The program offers lower-cost, refurbished testing instruments as well as customer education, inventory management, and enhanced service agreements.

Financial and other terms of the deal were not disclosed.

The all-virtual program is currently looking for a second cohort of novel diagnostics technologies, with a Sept. 30 deadline for new applications.

According to a company executive, the transactions will provide QuidelOrtho with greater financial flexibility while funding its continued growth.

The organization noted that US senators have introduced a bill to accelerate Medicare coverage for breakthrough devices.

NEW YORK — The Scottish government has earmarked £800,000 ($1.1 million) to support the introduction of a Genedrive test to help prevent antibiotic-induced deafness in newborns within the country, ...

TBI is a potential new application area for the 8-year-old company, while it continues to commercialize its stroke triage ...

Reviewers winnowed an initial 27 assays to a group of nine that were evaluated using NCI sample sets, ultimately choosing ClearNote's Avantect and Guardant's Shield.

UCLA's Electric Field-Induced Release and Measurement (EFIRM) system could offer the early detection of cancers and other diseases through a droplet-size saliva sample.

The MMR IHC Panel PharmaDx (Dako Omnis) is used to identify loss of function in mismatch repair proteins and inform the treatment of colorectal cancer patients.